Executives On The Move: Bio/Med Changes Made From Lilly And Amgen, And A Step Up R&D Ladder At Daiichi Sankyo
Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen Med Affairs exec becomes CMO at Matinas BioPharma Holdings. At Daiichi Sankyo, R&D leader steps up to Global Head, R&D position.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Diffusion Pharmaceuticals and WPD Pharmaceuticals get new chief medical officers.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.